Patient Perspectives and Experience with Dalfampridine Treatment in Multiple Sclerosis-Related Walking Impairment: The Step Together Program

BACKGROUND: Dalfampridine extended-release tablets (dalfampridine-ER; in Europe, prolonged-release fampridine, and elsewhere, fampridine modified or fampridine sustained release), 10 mg twice daily, are available for the treatment of improvement of walking in patients with multiple sclerosis, as dem...

Descripción completa

Detalles Bibliográficos
Autores principales: Crayton, Heidi, Sidovar, Matthew, Wulf, Stanley, Guo, Amy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2014
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445766/
https://www.ncbi.nlm.nih.gov/pubmed/25475652
http://dx.doi.org/10.1007/s40271-014-0102-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4445766/
https://www.ncbi.nlm.nih.gov/pubmed/25475652
http://dx.doi.org/10.1007/s40271-014-0102-z

Ejemplares similares